Post-Hoc: Rewatch the Boston edition of our China Biotech Debatenews2026-08-12T15:43:32+00:00August 12th, 2026|Endpoints News|
Boulevard Bio dreams big in immunology with $65M, sights on Vera’s IgAN drugnews2026-08-12T10:30:11+00:00August 12th, 2026|Endpoints News|
Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series Anews2026-08-11T12:00:44+00:00August 11th, 2026|Endpoints News|
BINSA legislation to limit biotech deals in China unveiled in Senatenews2026-08-07T16:35:22+00:00August 7th, 2026|Endpoints News|
China biotech will slow as it nears R&D frontier, Pfizer’s Baum predictsnews2026-08-07T15:00:01+00:00August 7th, 2026|Endpoints News|
Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3news2026-08-06T06:56:05+00:00August 6th, 2026|Endpoints News|
In a first, WuXi AppTec surpasses Lonza’s six-month revenue news2026-08-05T17:59:02+00:00August 5th, 2026|Endpoints News|
Expedition gets another $115M for its twist on China NewCo modelnews2026-08-05T12:00:01+00:00August 5th, 2026|Endpoints News|
The China Debate: Biotech deserves a deeper discussionnews2026-08-04T18:20:59+00:00August 4th, 2026|Endpoints News|
Pathos does deals with AstraZeneca, China’s Alphamab, seeks up to $300M Series Enews2026-08-04T00:00:51+00:00August 4th, 2026|Endpoints News|
